RESEARCH USE ONLY
This protocol template is a reference scaffold for laboratory, in-vitro, and animal-model research planning. It is not medical advice and is not intended for human administration. All ORYN peptides are sold strictly for research use.
BPC-157 Pen Recovery Research Protocol
BPC-157 (Body Protection Compound-157) is the most-replicated recovery-research peptide in the published literature, with over 500 peer-reviewed papers investigating its role in tissue repair, angiogenesis, and the nitric-oxide pathway. This protocol template is a reference scaffold for laboratory research studies using the ORYN BPC-157 peptide pen format — it is not human dosing guidance and is provided for research-use planning only.
DURATION
28-day research block
FREQUENCY
Daily administration, typically split across two time points
PEPTIDES
BPC-157
CATEGORY
Recovery & tissue repair
Pens used in this protocol
Scientific background
BPC-157 is a pentadecapeptide derived from a protective fragment of gastric juice. Research has investigated its effects on angiogenesis, the NO-pathway, growth-factor expression (including VEGF), and multiple tissue types — tendon, ligament, muscle, and gastrointestinal mucosa. Because it is orally bioavailable in some animal models and injectable in others, protocol design often depends on the specific tissue being investigated. The pen format matters for repeatability: the <2% click-variance means that the administered quantity in each research session is the same across the full 28-day block, which is one of the hardest variables to control in reconstitution-based workflows.
RESEARCH FOCUS
Localised and systemic tissue-repair, mucosal integrity, and nitric-oxide pathway studies
Protocol overview
Most referenced BPC-157 research protocols run a 28-day block with daily administration split into two time points (morning and evening), followed by a 14-day washout window before any follow-up block. The 28-day window aligns with tissue-repair cycle research and gives a clean measurement window for before/after endpoints. The split dosing pattern is driven by BPC-157's short half-life — administering at two time points maintains more stable exposure than a single daily bolus.
Protocol phases
PHASE 1
Baseline week (days -7 to 0)
DURATION
7 days
DIAL SETTING
No administration — baseline measurements only
Record baseline endpoints before administration begins: imaging, biomarker panels, mobility-range measurements, or any study-specific endpoint. This baseline window is the reference point the post-protocol measurements will be compared against.
PHASE 2
Loading phase
DURATION
Days 1-14
DIAL SETTING
Higher-range dial setting, split morning/evening
The first two weeks typically run at a higher daily administered amount to establish the research exposure. The pen's dial-a-dose makes this phase trivial: set the dial once, administer, repeat evening. The exact click count for the loading phase depends on the specific research question and published literature being referenced.
PHASE 3
Maintenance phase
DURATION
Days 15-28
DIAL SETTING
Reduced dial setting, continued twice-daily
Weeks 3-4 step down to a maintenance range to extend the exposure window without over-administering. This is where consistent click accuracy matters most — any drift in the administered amount across the 14 days of maintenance phase would introduce dose-variance noise into the endpoint data.
PHASE 4
Washout
DURATION
Days 29-42
DIAL SETTING
No administration
A 14-day washout window before any follow-up block or second research cycle. Post-protocol endpoint measurements typically happen at day 42 to capture delayed tissue-repair effects.
Key considerations
- •Research-use only. This protocol is for laboratory, in-vitro, and animal-model research planning — not human administration.
- •BPC-157 has a short half-life in most animal models, so split-dosing maintains more stable exposure than single daily administration.
- •Storage matters: the ORYN BPC-157 pen is stable refrigerated for the duration of the 28-day block. Freezing is not required and is not recommended during an active research block.
- •Reconstitution is pre-handled — the pen ships in ready-to-use format, so there is no reconstitution variance between research sessions.
- •Record the batch ID and CoA reference at the start of the research block. If the protocol is repeated, use the same batch across both runs to eliminate lot-to-lot variance.
Why the pen format for this protocol
- →Click-accuracy <2% variance means the administered amount is the same across all 28 days of the research block.
- →Pre-mixed format removes reconstitution variance — no measurement error from bacteriostatic water dilution.
- →Dial-a-dose lets you step down from loading phase to maintenance phase by changing a single setting, no new vial required.
- →Cold-chain only at dispatch — once received, refrigeration is sufficient for the full block, no freeze/thaw cycles.
- →Batch-locked CoA stays constant across the 28-day block, so endpoint data maps to a single potency specification.
Literature references
The most commonly cited BPC-157 research references include work on Achilles tendon healing (Staresinic et al.), muscle crush injury recovery (Novinscak et al.), and nitric-oxide pathway modulation (Sikiric et al.). Any serious protocol should reference the specific published paper being replicated or extended — protocol design varies significantly depending on whether the research focus is tendon, muscle, mucosal, or systemic. The 28-day window described here is the most commonly used duration for tissue-repair research and is not intended as a universal recommendation.
STACKING OPTIONS
BPC-157 is frequently stacked with TB-500 (thymosin beta-4 fragment) in the published literature — the two target complementary mechanisms, with BPC-157 driving local tissue response and TB-500 driving systemic cell migration. If the research question involves combined-mechanism studies, both pens can run in parallel on the same 28-day block. The ORYN BPC-157 pen and TB-500 pen are independent research units with independent CoAs, so stacking does not require any reformulation.
Common research endpoints
◆
Imaging endpoints (ultrasound, MRI) for tissue-repair research
◆
Biomarker panels: VEGF, collagen synthesis markers, inflammatory cytokines
◆
Functional endpoints: mobility range, load-bearing, grip-strength in animal models
◆
Histological endpoints at the end of the research block
◆
Safety / tolerability endpoints throughout the protocol
FAQ
Is this a human dosing protocol?
No. This is a research-use protocol template for laboratory and animal-model research only. It is not medical advice and is not intended for human administration. All ORYN peptides are sold strictly for research use.
Why 28 days specifically?
28 days aligns with the most commonly referenced tissue-repair research cycle in the BPC-157 literature and gives a clean window for before/after endpoint measurement. Some protocols use 14-day or 42-day windows depending on the specific research question.
Does the pen format change the protocol?
The pharmacology is identical to any other BPC-157 delivery method. What changes is reproducibility: <2% click variance and pre-mixed reconstitution remove two of the biggest sources of administered-amount drift, which matters when running endpoint comparisons across the full 28-day block.
Can I run BPC-157 and TB-500 on the same block?
Yes — this is a common research design. Both peptides run independently with their own CoAs and batch IDs, and the research literature frequently investigates the combined mechanism. The stacking protocol uses both pens on the same 28-day timeline, no reformulation required.
What about the washout window?
The 14-day washout is a research-hygiene practice — it gives a clean measurement window before any follow-up block, and it aligns with the half-life characteristics observed in the animal-model literature. Protocols that investigate continuous-exposure research designs may omit the washout, but most replicable published work uses a clear washout before the next cycle.
Order the pens for this research protocol
Every ORYN peptide pen ships with a Certificate of Analysis, full batch documentation, and the pen-format mechanical accuracy that makes protocol replicability possible. Research use only.
OTHER RESEARCH PROTOCOLS
METABOLIC & INCRETIN RESEARCH
Tirzepatide metabolic
12-week research block · Weekly single administration
GH-AXIS RESEARCH STACK
GH-axis stack
12-week research block · Twice-daily split administration (morning and pre-sleep)
LONGEVITY & MITOCHONDRIAL RESEARCH
NAD+ longevity
8-week loading + maintenance block · Daily during loading, alternate-day during maintenance
SKIN & COLLAGEN RESEARCH
GHK-Cu skin
6-week research block · Daily single administration